Yahoo India Web Search

Search results

  1. Vertex is a biotechnology company that develops and commercializes drugs for serious diseases. Learn about its latest news, acquisitions, financial results, corporate responsibility and pain program.

    • Our Company

      Vertex Pharmaceuticals strikes at the core of serious...

    • Careers

      Important Notices: Recruitment & Staffing Agencies: Vertex...

    • Medicines

      Vertex’s Inclusion, Diversity and Equity Priorities Our...

    • Patients

      Creating transformative medicines truly takes a village....

    • Responsibility

      Vertex was named one of America’s Most Responsible Companies...

    • Investors

      Contacting Vertex's Transfer Agent. Communication regarding...

    • News & Events

      Vertex’s VX-880, an investigational allogeneic stem...

  2. Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.

  3. Vertex is a biopharmaceutical company that creates transformative medicines for people with serious diseases. Learn about their mission, values, culture, R&D and recognition.

  4. Dec 8, 2023 · CASGEVY is a CRISPR/Cas9 genome-edited cell therapy for sickle cell disease (SCD) that offers the potential of a functional cure by reducing vaso-occlusive crises. Vertex leads global development and commercialization of CASGEVY, with support from CRISPR Therapeutics.

  5. Find the latest Vertex Pharmaceuticals Incorporated (VRTX) stock quote, history, news and other vital information to help you with your stock trading and investing.

  6. May 30, 2024 · A new era of personalized medicine began last fall when the U.S. and other countries gave the first-ever approvals to a treatment based on CRISPR gene editing: Casgevy, developed by Vertex and...

  7. Jul 11, 2022 · Vertexs VX-880, an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy for T1D, has already achieved proof-of-concept with highly promising safety and efficacy results from an ongoing Phase 1/2 study which continues to enroll and dose patients.